216394-05-7

Basic information

• Product Name: 5-Bromo-6-chloropyridine-3-sulfonyl chloride
• Synonyms: AURORA 23186;3-BROMO-2-CHLOROPYRIDINE-5-SULFONYL CHLORIDE;3-BROMO-2-CHLOROPYRIDINE-5-SULPHONYL CHLORIDE;5-BROMO-6-CHLORO-3-PYRIDINE SULFONYL CHLORIDE;5-BROMO-6-CHLOROPYRIDINE-3-SULFONYL CHLORIDE;AKOS BBS-00001320;3-Bromo-2-chloropyridine-5-sulfonyl Chlorid;5-Bromo-6-chloropyridine-3-sulphonyl chloride
• CAS NO: 216394-05-7
• Molecular Formula: C₅H₂BrCl₂NO₂S
• Molecular Weight: 290.95
• EINECS: -0
• Product Categories: Pyridines;Sulphonyl Chlorides;Pyridine;Aromatics Compounds;Aromatics;Sulfonyl Chlorides;Sulfur & Selenium Compounds;Sulphonyl Chlorides;Pyridine Series;Heterocycle-Pyridine series
• Mol File: 216394-05-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 71-73°C
• Boiling Point: 352.8 °C at 760 mmHg
• Flash Point: 167.2 °C
• Appearance: /
• Density: 1.973g/cm³
• Vapor Pressure: 7.62E-05mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane
• PKA: -6.06±0.10(Predicted)
• Water Solubility: Reacts with water. Soluble in dichloromethane.
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 5-Bromo-6-chloropyridine-3-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-6-chloropyridine-3-sulfonyl chloride(216394-05-7)
• EPA Substance Registry System: 5-Bromo-6-chloropyridine-3-sulfonyl chloride(216394-05-7)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-36
• Safety Statements: 26-36/37/39
• RIDADR: 3261
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 216394-05-7(Hazardous Substances Data)

Usage

Description

5-Bromo-6-chloropyridine-3-sulfonyl chloride is an organic compound characterized by its pale yellow solid appearance. It is a chemical intermediate that holds significant importance in various industrial applications due to its unique chemical properties.

Uses

Used in Organic Synthesis:
5-Bromo-6-chloropyridine-3-sulfonyl chloride is used as a key intermediate for organic synthesis, facilitating the creation of a wide range of chemical compounds. Its unique structure allows for versatile reactions, making it a valuable component in the synthesis of various molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-6-chloropyridine-3-sulfonyl chloride is utilized as a crucial building block for the development of new drugs. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacological properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemicals:
5-Bromo-6-chloropyridine-3-sulfonyl chloride is also employed in the agrochemical sector as an intermediate for the synthesis of various agrochemical products. Its use in this industry aids in the development of more effective and targeted pesticides, herbicides, and other agricultural chemicals.
Used in Dyestuff Field:
In the dyestuff field, 5-Bromo-6-chloropyridine-3-sulfonyl chloride is used as an intermediate for the production of dyes and pigments. Its chemical properties enable the creation of a diverse array of colorants, contributing to the vibrancy and variety of colors available in the market.
Overall, 5-Bromo-6-chloropyridine-3-sulfonyl chloride is a versatile and essential compound in multiple industries, playing a critical role in the development and synthesis of various products, from pharmaceuticals to dyes.

InChI:InChI=1/C5H2BrCl2NO2S/c6-4-1-3(12(8,10)11)2-9-5(4)7/h1-2H

Upstream product

• 109-01-3 1-methyl-piperazine 
• 247582-62-3 2-Amino-3-bromopyridine-5-sulphonic Acid 
• 504-29-0 2-aminopyridine 
• 16250-08-1 pyridine-2-amino-5-sulphonic acid 

Downstream Products

• 849349-02-6 5-bromo-N-[2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-6-chloro-N-methylpyridine-3-sulfonamide 
• 1310537-00-8 4-(3-bromo-5-(N,N-diethylsulfamoyl)pyridin-2-yl)-N-phenylpiperazine-1-carboxamide 
• 622815-46-7 5-bromo-6-chloro-N,N-diethylpyridine-3-sulfonamide 
• 1353433-10-9 4-(5-bromo-6-chloro-pyridine-3-sulfonylamino)-2-hydroxy-benzoic acid 
• 247582-73-6 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic Acid 
• 1357279-09-4 (1r,4r)-4-(6-(allyl(methyl)amino)-5-bromopyridine-3-sulfonamido)-N-((R)-1-(4-fluorophenyl)ethyl)cyclohexanecarboxamide 
• 1357271-88-5 (1r,1r)-4-(1,3-dimethyl-1H-pyrrolo[2,3-b]pyridine-5-sulfonamido)-N-((R)-1-(4-fluorophenyl)ethyl)cyclohexanecarboxamide 
• 1310475-05-8 trans-4-(5-bromo-6-chloro-pyridine-3-sulfonylamino)-cyclohexanecarboxylic acid [(R)-1-(4-fluoro-phenyl)-ethyl]-amide 
• 622815-22-9 C₈H₈BrClN₂O₂S 
• 1447647-67-7 C₁₁H₁₂BrClN₂O₂S 
• 1447647-68-8 C₁₂H₁₄BrClN₂O₂S 
• 1450621-10-9 2-(4-((2S)-4-((6-amino-5-bromo-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1450621-11-0 3-bromo-5-(((3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinyl)sulfonyl)-2-pyridinol 
• 1450621-14-3 2-amino-5-(((3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinyl)sulfonyl)-3-pyridinecarbonitrile 

Relevant articles and documents

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published.2,3.

PHENOXY ACETIC ACID DERIVATIVES

The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.

Treatment of diabetic ulcers

This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic ulcers, particularly diabetic foot ulcers.